Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) announced several governance adjustments effective 23 March 2026. Joint Company Secretary Sze Suet Ling will resign from her roles as Joint Company Secretary, Hong Kong Agent for Service of Process and Authorised Representative due to personal career plans.

Industry veteran Mak Po Man Cherie, currently Vice President of SWCS Corporate Services Group (Hong Kong) Limited, will assume the three vacated positions on the same date. Mak brings more than 20 years of audit, accounting, corporate finance, compliance and corporate secretarial experience, and holds professional memberships with The Hong Kong Chartered Governance Institute, The Chartered Governance Institute, the Hong Kong Institute of Certified Public Accountants and the Association of Chartered Certified Accountants.

Yang Dongyan, appointed Joint Company Secretary on 6 February 2026, will remain in her position and continue to serve as Innogen Pharmaceutical’s legal director.

The Stock Exchange of Hong Kong granted a new waiver allowing Yang to continue serving as Joint Company Secretary without meeting the full experience requirements under Listing Rules 3.28 and 8.17. The waiver is valid until 5 February 2029, provided Yang is assisted by Mak and no material Listing Rules breaches occur. Before the waiver expires, Innogen Pharmaceutical must demonstrate that Yang has gained sufficient experience to discharge company-secretary duties independently.

The board expressed appreciation for Sze’s contributions and welcomed Mak to her new roles.